ACG, a leading supplier of integrated pharmaceutical manufacturing solutions announced acquisition of a significant stake in Mumbai-based startup IQGEN-X.
The move sees ACG expanding further into the R&D side of drug development.
It also comes at what the company describes as a critical juncture, when the Indian government is at the cusp of announcing policy to incentivise innovation in science. The funds received by ACG will be utilised for setting up a cGMP facility and also the development & filing of abbreviated new drug applications (ANDAs).
“IQGENX’s excellent track record in patents and ANDAs speaks for itself, and we look forward to benefitting from its niche technology, broad-based expertise and research specialisation that has been recognised globally by WHO and the US FDA,” said Karan Singh, Managing Director, ACG. “For ACG, this partnership will immediately help expand our group capabilities, and will accelerate our innovation strategy of bold, disciplined investment and world class execution to drive sustainable long-term growth with drug companies in India and global markets."
Dr Mandar M Kodgule, Chairman & CEO, IQGEN-X commented that “We at IQGEN-X are delighted to have ACG as partner whose strong global footprints and excellent operational capabilities, bring great synergy to IQGEN-X’s growth strategy. ACG's strategic investment augments our technical expertise, portfolio strategy and corporate vision to create a robust portfolio of limited competition complex products for regulated markets. We believe that this partnership will open several other opportunities which will accelerate growth of both companies.”
IQGENX was established in October 2016, with a vision of “innovative research and technology to produce high quality, affordable, safe, and effective medicines”. With an R&D facility for niche and complex generic products, expertise in technology transfer, regulatory, IP and compliance, the company caters to US, European and other highly regulated markets.
